Illumina, Inc. $ILMN Shares Sold by BI Asset Management Fondsmaeglerselskab A S

Key Points

• BI Asset Management Fondsmaeglerselskab A S reduced its stake in Illumina, Inc. by 85.4%, ending the quarter with 6,203 shares valued at approximately $492,000.
• Illumina's recent earnings report showed an EPS of $1.19, exceeding estimates but with revenue decreasing by 4.8% year-over-year.
• The stock has a current market performance with a P/E ratio of 12.89 and is trading around $101.80, while analysts generally rate it as a "Hold" with an average target price of $124.58.

BI Asset Management Fondsmaeglerselskab A S cut its holdings in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 85.4% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 6,203 shares of the life sciences company's stock after selling 36,201 shares during the period. BI Asset Management Fondsmaeglerselskab A S's holdings in Illumina were worth $492,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in ILMN. Fourth Dimension Wealth LLC acquired a new position in Illumina during the 4th quarter valued at about $40,000. Rakuten Securities Inc. grew its stake in shares of Illumina by 290.3% during the first quarter. Rakuten Securities Inc. now owns 363 shares of the life sciences company's stock worth $29,000 after acquiring an additional 270 shares during the last quarter. Center for Financial Planning Inc. purchased a new stake in shares of Illumina during the first quarter worth about $33,000. PFS Partners LLC increased its holdings in shares of Illumina by 400.0% during the first quarter. PFS Partners LLC now owns 500 shares of the life sciences company's stock valued at $40,000 after acquiring an additional 400 shares in the last quarter. Finally, Golden State Wealth Management LLC raised its position in shares of Illumina by 123.2% in the 1st quarter. Golden State Wealth Management LLC now owns 529 shares of the life sciences company's stock valued at $42,000 after purchasing an additional 292 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company's stock.

Illumina Stock Performance

NASDAQ ILMN opened at $101.80 on Friday. The firm has a market capitalization of $15.65 billion, a P/E ratio of 12.89, a PEG ratio of 2.29 and a beta of 1.37. The stock has a 50-day simple moving average of $98.18 and a two-hundred day simple moving average of $88.88. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.41 and a current ratio of 1.81. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its earnings results on Thursday, July 31st. The life sciences company reported $1.19 EPS for the quarter, topping analysts' consensus estimates of $1.02 by $0.17. The firm had revenue of $1.06 billion for the quarter, compared to the consensus estimate of $1.12 billion. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The company's revenue was down 4.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.36 earnings per share. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. On average, equities analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on ILMN shares. Robert W. Baird upped their price target on shares of Illumina from $84.00 to $105.00 and gave the company a "neutral" rating in a research note on Monday, July 28th. Evercore ISI upped their target price on Illumina from $116.00 to $128.00 and gave the company an "outperform" rating in a research report on Tuesday, July 8th. Barclays raised their target price on Illumina from $85.00 to $90.00 and gave the stock an "underweight" rating in a research note on Friday, August 1st. Citigroup downgraded Illumina from a "hold" rating to a "strong sell" rating and dropped their price target for the company from $85.00 to $80.00 in a research note on Wednesday, July 9th. Finally, Daiwa Capital Markets cut Illumina from an "outperform" rating to a "neutral" rating and set a $94.00 price objective for the company. in a research note on Tuesday, August 12th. Seven equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $124.58.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.